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Multi-drug resistant malaria parasite strains have spread to 
new areas that were once free of such strains. This study 
evaluated the specific in vitro sensitivities of some standard 
antimalarial drugs, against Plasmodium falciparum isolates in 
Makurdi, North Central Nigeria. The standard schizonts growth 
inhibition assays was used to study the in vitro activities of 
quinine, artesunate, and amodiaquine against 146 isolates in 
children aged 2-14 years. 100 % of isolates were in vitro 
sensitive to quinine, geometric mean effective concentration 
(EC)50 = 241.55 nM, EC90 = 676.08 nM, and EC99 = 993.12 nM; 
and artesunate, EC50 = 1.05 nM, EC90 = 2.42 nM, and EC99 = 
3.16 nM. 1.37 % of isolates were resistant to amodiaquine, 
EC50 = 22.08 nM, EC90 = 66.22 nM and EC99 = 100.23 nM. 
Significant in vitro cross resistance was found at EC50 values 
of quinine-amodiaquine drug pair (r = + 0.342, P < 0.05), but 
not quinine – artesunate (r = + 0.057, P > 0.05) or artesunate-
amodiaquine (r = + 0.088, P > 0.05). These results call for 
constant surveillance, to curb the spread of P. falciparum 
resistance to amodiaquine in Nigeria. 
   




Malaria continues to be of great public health concern to many 
countries in the world. Recent estimates by the World Health 
Organization (WHO, 2009) revealed that half of the world 
population is at the risk of malaria and that 243 million people 
experienced clinical malaria in 2008, resulting in 863,000 deaths 
worldwide out of which 89 % occurred in Africa. In areas where 
Plasmodium falciparum is the most dominant causative agent of 
the disease, the impact of malaria, on the resident population has 
been very huge (Cooper et al., 1998). The worsening impact of 
falciparum malaria has continued mainly because of the rising 
wave of drug resistant malaria (Olliaro, 2005). In Nigeria, 
resistance to chloroquine and sulfadoxine/pyrimethamine by P. 
falciparum has been reported (Salako & Aderounmu, 1987; 
Olurinola, 1989; Abdullahi et al., 2003; Oguche et al., 2004; 
Pitmang et al., 2005). Worldwide, drug resistance has thwarted 
efforts at malaria control (Olliaro, 2005). This has led to the need 
for constant surveillance and monitoring for changes in malaria 
parasites sensitivity to different antimalarial drugs and the rapid 
switch to artemisinin combination therapies (ACTs), for the 
treatment of malaria (Kremsner & Krishna, 2004; Olliaro & Taylor, 
2004). Even though the use of ACTs together with insecticide 
treated bed nets has seen the reduction in malaria morbidity 
(Barnes et al., 2009), in vivo resistance to artemisinins that were 
thought be immuned is still being reported (Dondorp et al., 2009).  
 
The in vitro drug susceptibility test is an invaluable tool for the 
surveillance of drug resistant malaria worldwide (WHO, 2001; 
Plowe, 2003). It provides an alternative to clinical studies in malaria 
endemic areas, where drug susceptibility of parasite isolates can 
be obscured by different levels of acquired immunity in patients 
treated with antimalarial drugs (Russel et al., 2003). In Nigeria, 
data on the susceptibility profile of P. falciparum isolates to 
antimalarial drugs are sparse. However, it is imaginable that 
resistant P. falciparum, may have contributed reasonably to the 
malaria burden in the country. The aim of this study was to 
determine the baseline level of in vitro sensitivities of P. falciparum 
isolates to selected antimalarial drugs used in north central Nigeria, 
and to generate baseline data for future monitoring of parasite 
responses to those antimalarial drugs in the region. 
 
MATERIALS AND METHODS 
Study site: The study was conducted at the Bishop Murray 
Medical Centre, and the Federal Medical Centre, all in Makurdi, 
north central Nigeria. The study protocol was approved by the local 
ethics committee of each hospital, and lasted from October 2005 to 
December 2006.  
  
Subjects: Enrolled subjects were febrile symptomatic children 
aged 2-14 years, who reported to the hospital with a history of 
fever, and whose guardian gave written informed consent. Prior to 
treatment, 2.5ml of venous blood was collected into heparin treated 
tubes, for microscopic detection of P. falciparum mono infections 
with Giemsa stain, and in vitro drug susceptibility test. Subjects 
with symptoms of severe malaria infections, a recent history of 
malaria pre-treatment with antimalarial drugs, and confirmed 
severe anaemia (PCV ≤ 21%) were excluded from the study. 
Confirmed P. falciparum mono infections with parasite density of 
2,000 to 80,000 asexual forms per µl of blood were included in the 
in vitro test (WHO, 2001). 
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Antimalarial drug dilutions and plates preparation: Stock 
solutions, 1mg/ml of antimalarial drugs, amodiaquine, artesunate 
and quinine (Sigma Aldrich) were each prepared in an appropriate 
solvent. The solutions were sonicated and filtered with 0.22 µm 
membrane filter (Millipore). A further dilution of each stock was 
made to yield a working solution of desired concentration. From the 
working solutions, two fold serial dilutions were performed on a 96-
well flat bottom micro culture plate, and the plates dried in an 
incubator at 37 оC (Russel et al., 2003). The range of the final drug 
concentrations were, amodiaquine: 6.25 – 400 nM; artesunate: 
0.34 – 22 nM; and quinine: 50 – 3200 nM.  
 
In vitro cultivation of Plasmodium falciparum isolates and 
drug susceptibility test: The in vitro cultivation of P.  falciparum 
isolates followed a modification of the standard culture techniques 
(Trager & Jensen, 1976; Haynes et al., 1976), while drug 
susceptibility test followed the standard procedure for schizonts 
inhibition (WHO, 2001). The culture medium consisted of 10.43g 
RPMI 1640 (Invitrogen), 5.96g HEPES, and 25mM NaHCO3 
(Sigma Aldrich), per litre of double distilled water, supplemented 
with 5% albuamax II (Gibco) (Cranmer et al., 1997). The medium 
was sterilized by filtration through 0.22 µm membrane filter, and 
addition of 0.5ml of 50mg/ml gentamicin. 200µl of a 1:20 dilution of 
malaria positive blood, from each patient was transferred to wells 
on the micro culture plates, pre-dosed with varying concentrations 
of antimalarial drugs. The plates were placed in a candle jar, and 
incubated at 37°C, for 26-30 hrs (WHO 2001), at the end of the 
incubation period, thick films were made, and stained with 2.5% 
Giemsa stain for 35 mins.  The mean number of schizonts formed 




Determination of in vitro effective concentration (EC) values of 
the antimalarial drugs: The mean number of schizonts counts per 
well, were fed directly into non linear regression software, HN-
NonLin, specific for malaria in vitro drug sensitivity test. Individual 
dose response curves were generated, and their EC50, EC90, and 
EC99 values determined. Standard drug resistant clones were not 
included in the assay. However, drug resistant P. falciparum 
parasites were identified as isolates with EC50 or EC99 values 
greater than published threshold values for sensitive parasite 
isolates. The threshold of resistance were; quinine: EC50 >500 nM 
or EC99 > 2560 nM; amodiaquine: EC50 > 80 nM, or EC99 > 400 nM 
(Pradines et al., 1998; WHO, 2001; Pradines et al., 2006).  For 
Artesunate, threshold EC50 and EC99 values for in vitro resistance 
have not yet been determined (Noedl et al., 2003), therefore the 
estimated EC values were reported as a baseline data for future 
comparison.  
 
Data Analysis: The geometric means and 95 % confidence 
intervals (CI) of EC values were estimated. Pearson correlation 
coefficient was used to determine correlation between drug pairs.  
In each case the level of significance was set at P ≤ 0.05. 
 
RESULTS 
Out of 174 parasite isolates tested in vitro, 146 (83.91%) yielded 
complete data for the determination of EC values for the three 
drugs tested. The geometric mean EC values for each drug and 
their 95% confidence intervals (CI) are shown in Table 1. In vitro 
resistance to amodiaquine - isolates with EC50 > 80 nM among the 
cultured isolates was 1.37% or (2/146). No resistant isolates were 
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FIG. 1. RELATIVE EC50 (nM) DISTRIBUTION PATTERNS OF ARTESUNATE  





TABLE 1. GEOMETRIC MEAN EC50 EC90 AND EC99, 95% CONFIDENCE INTERVAL (CI) OF  
ANTIMALARIAL DRUGS AGAINST Plasmodium falciparum ISOLATES, N = 146. 
 
Geometric Mean EC, (95% CI) nanomolar (nM) Drugs          EC50          EC90          EC99 
Artesunate 1.05 (1.03 – 1.07) 2.42 (2.37 – 2.47) 3.16 (3.07 – 3.26) 
Amodiaquine 22.08 (20.75 – 23.44) 66.22 (61.38 – 71.45) 100.23 (93.11 - 107.89) 
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FIG. 2. RELATIVE EC50 (nM) DISTRIBUTION PATTERNS OF AMODIAQUINE  
AMONG P. falciparum ISOLATES AT MAKURDI 
 







































FIG. 3. RELATIVE EC50 (nM) DISTRIBUTION PATTERNS OF QUININE  
AMONG P. falciparum ISOLATES AT MAKURDI 
 
Although no in vitro resistance cut off values have been reported 
for artesunate, the EC values of individual isolates against the 
drug were very low, and fell within the range of EC50 values 
previously reported for sensitive isolates to the drug, or its active 
metabolite, dihydroartemisinin (Noedl et al., 2003; Woodrow et 
al., 2005; Pradines et al., 2006; Tinto et al., 2006). 
 
Correlation of in vitro responses of P. falciparum EC50 values of 
antimalarial drug pairs showed significant positive in vitro cross 
resistance between quinine-amodiaquine (r = + 0.342; P < 0.05), 
but not between quinine-artesunate (r = + 0.057), or artesunate-
amodiaquine (r = + 0.088; P > 0.05) (Table 2). 
 
TABLE 2. CORRELATION OF IN VITRO RESPONSES OF P. falciparum ISOLATES BETWEEN 









The present results show that there was a one hundred percent in 
vitro sensitivity of P. falciparum fresh parasite isolates to artesunate 
and quinine in the study area but very low in vitro parasite 
resistance (1.37%) against amodiaquine. However, the very low 
levels of in vitro P. falciparum resistance against the latter drug 
demonstrated that the over all in vitro sensitivities of amodiaquine, 
like quinine, and artesunate, were equally very high in this area. 
These findings, regarding the sensitivities of amodiaquine, 
represent a sharp contrast from the results obtained by Oyedeji et 
al., (2005) in south western Nigeria in which, 39% of 36 P. 
falciparum isolates were reported to be in vitro resistant to 
amodiaquine.  The corresponding  mean  EC50,  EC90,   and   EC99  
 
 
values of amodiaquine against P. falciparum were 0.06 µM, 
0.26µM, and 0.59µM respectively (Oyedeji et al., 2005). Compared 
to the present EC values, the potency ratio of amodiaquine in south 
west Nigeria was approximately 3 fold; 4 fold; and a 6 fold 
decrease over Makurdi, at corresponding EC levels. This suggests 
that P. falciparum isolates in Makurdi, north central Nigeria, were 
more sensitive to amodiaquine, than strains circulating in south 
western Nigeria. 
 
The present EC50 and EC99 values of quinine are comparably close 
to the corresponding inhibitory concentration - IC50 and IC99 values 
of 0.25 µM and 0.80 µM respectively, reported almost two decades 
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ago also in south western Nigeria (Salako et al., 1988). These 
values compared to the present EC values approximately yielded a 
potency ratio of 1 at corresponding EC levels. Implying that, the in 
vitro sensitivities of circulating strain of P. falciparum isolates to 
quinine, between the south west, and north central regions in the 
country, have remained relatively very stable; despite nearly two 
decades of use, since the re-introduction of quinine antimalarial 
drug, in the country. Like in many other countries, quinine has 
mainly being used in Nigeria for the treatment of severe and drug 
resistant falciparum malaria, usually under medical supervision 
(Abdullahi et al., 2003). Relevant data suggests that quinine is also 
very effective else where in West Africa (Agnamey et al., 2006). 
The absence of in vitro P. falciparum resistance to quinine, in this 
study, and the apparent stability of in vitro responses of P. 
falciparum to quinine in Nigeria over a long period of time, suggests 
its continued relevance for resolving malaria infections in the 
country.  
 
Amodiaquine has quickly assumed the position of its sister 
analogue, chloroquine as an alternative drug for the treatment of 
uncomplicated malaria in the country with higher efficacies, due to 
high levels of parasite resistance to the latter (Molta et al., 2003). It 
is readily available across the counter in this country for self 
treatment of malaria, and could therefore be subjected to irrational 
use, during self treatment. The low levels of in vitro resistance 
observed against the drug in the present study, and elsewhere in 
the country (Oyedeji et al., 2005) suggests an imminent threat of 
wide scale parasite resistance to the drug. It also calls for the need 
for constant surveillance and vigilance to curb the imminent spread 
of drug resistant strains of P. falciparum in the country.  
  
The artesunate antimalarial is a relatively new entrant on the scene 
in Nigeria with little information about the drug. The drug is also 
readily available in major cities in the country, but its average cost 
makes it prohibitive for wanton self purchase and self treatment for 
an average Nigerian. Currently, artesunate plus amodiaquine, is 
also used for the treatment of uncomplicated malaria in the 
country. Emerging in vivo data else where, and in Nigeria suggests 
some encouraging development in this regard (Mutabingwa et al., 
2005; Agnamey et al., 2006; Meremikwu et al., 2006; Djimde et al., 
2008). There is also the fear that full scale deployment of 
artesunate plus amodiaquine for the home management of malaria 
as it is being considered may result in complete failure of the 
combination in the near future, particularly due to non compliance 
with the treatment regimen as a result of adverse reactions to 
amodiaquine. This may fuel the early loss of both drugs, thus the 
deployment of artesunate plus amodiaquine combination for the 
self home management of malaria should proceed with caution. 
The combination should not be prescribed and administered as 
non fixed combination without supervision. It should be routinely 
administered otherwise, only when a reliable fixed dose 
combination with minimum contraindications, produced in blister 
pack with a short treatment period has been produced.  
 
The present data did not observe significant in vitro cross 
resistance between artesunate and quinine as has been reported 
by others (Noedl et al., 2003) but cross resistance did exist 
between quinine and amodiaquine in agreement with previous 
findings (Pradines et al., 1998). Considering the high in vitro 
sensitivities of quinine, and artesunate observed, and the lack of in 
vitro cross resistance between the two drugs, it could be possible 
to combine quinine and artesunate for the management of severe 
malaria. This would parallel the combination between amodiaquine 
and artesunate, being used for the management of acute malaria 
(Kremsner and Krishna 2004; Mutabingwa et al., 2005; Meremikwu 
et al., 2006; Djimde et al., 2008; Oyakhirome et al., 2007) Already, 
synergy between artesunate and quinine has been reported in vitro 
(Fivelman et al., 1999). Thus, artesunate plus quinine combination 
in areas with high P. falciparum parasite sensitivities to these drugs 
as in the present instance would engender two plausible 
possibilities. Namely, to achieve effective and high cure rates for 
both severe and acute clinical malaria, and to prolong the vital 
therapeutic life of both antimalarial agents.  
 
In conclusion, the present data has demonstrated high in vitro 
sensitivities of artesunate, amodiaquine and quinine against P. 
falciparum isolates in this area, albeit low levels of in vitro 
resistance to amodiaquine. Subsequent surveys should in addition 
to the present procedure integrate both in vivo and molecular 
surveillance, in order to characterize the true nature of P. 
falciparum isolates in this area. Such efforts are necessary in order 
to evolve appropriate controls measures against the spread of drug 
resistant parasite strains.     
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